{"gene":"PLCB1","run_date":"2026-06-10T06:43:35","timeline":{"discoveries":[{"year":1988,"finding":"PLC-154 (PLCB1) encodes a functional phosphoinositide-specific phospholipase C of ~150 kDa. The central region of PLC-154 shares homology with PLC-148 and was assigned as the putative catalytic domain. Transient expression in COS-1 cells confirmed the encoded protein is enzymatically active.","method":"cDNA cloning, transient expression in COS-1 cells, protein sequence analysis, Southern/Northern blotting","journal":"Cell","confidence":"High","confidence_rationale":"Tier 1 / Strong — direct reconstitution of enzymatic activity from cloned cDNA, domain assignment by sequence homology with functional validation","pmids":["2455601"],"is_preprint":false},{"year":2014,"finding":"The PLCB1 promoter was characterized for the first time; transcription initiates from multiple start points, with the main start at nt-235 relative to the translation start. A specific EGR-1 binding site was identified at nt-451/-419, and EGR-1 overexpression increased PLCB1 promoter activity more than 5-fold, placing EGR-1 as a direct transcriptional activator of PLCB1.","method":"5'-RACE, promoter cloning, luciferase reporter assays with deletion constructs, EMSA, EGR-1 overexpression in multiple cell lines","journal":"European journal of pharmacology","confidence":"High","confidence_rationale":"Tier 1-2 / Moderate — multiple orthogonal methods (EMSA, luciferase deletion constructs, overexpression) in a single focused study","pmids":["25192965"],"is_preprint":false},{"year":2021,"finding":"PLCB1 activates PI3K/AKT signaling to induce epithelial-to-mesenchymal transition (EMT) in cholangiocarcinoma cells. PABPC1 physically interacts with PLCB1 and PI3K to amplify PLCB1-mediated EMT via the PI3K/AKT/GSK3β/Snail axis. PLCB1-driven AKT activation also confers resistance to gemcitabine/cisplatin, reversible by the AKT inhibitor MK2206.","method":"Co-immunoprecipitation (PABPC1–PLCB1–PI3K interaction), transposon-based in vivo tumorigenesis models, siRNA knockdown/overexpression, drug treatment with pathway inhibitor","journal":"Cancer research","confidence":"Medium","confidence_rationale":"Tier 2-3 / Moderate — Co-IP for interaction, multiple functional assays, in vivo models; single lab","pmids":["34580062"],"is_preprint":false},{"year":2021,"finding":"HDAC8 upregulates PLCB1 expression in MEK1/2 inhibitor-resistant cancer cells, and elevated PLCB1 activates AKT, contributing to resistance. HDAC8 inhibition suppresses PLCB1 expression and re-sensitizes resistant cells to MEK1/2 inhibition; PLCB1 siRNA similarly inhibits AKT activation.","method":"Affymetrix microarray followed by qPCR validation, siRNA knockdown of HDAC8 and PLCB1, HDAC8 inhibitors, expression vectors, AKT activity assays","journal":"Cells","confidence":"Medium","confidence_rationale":"Tier 2-3 / Moderate — multiple orthogonal methods (microarray + qPCR + siRNA + inhibitor), single lab","pmids":["34064422"],"is_preprint":false},{"year":2023,"finding":"PLCB1 promotes gastric cancer cell migration and invasion by mediating actin cytoskeletal remodeling via the RhoA/LIMK/Cofilin pathway and by promoting EMT through AKT signaling. PLCB1 regulates the abundance of PI(4,5)P2 at the plasma membrane as part of this mechanism.","method":"siRNA knockdown, overexpression, cell migration/invasion assays, Western blot for RhoA/LIMK/Cofilin and AKT pathway components","journal":"Biochemical genetics","confidence":"Medium","confidence_rationale":"Tier 2-3 / Moderate — loss- and gain-of-function with specific pathway readouts; single lab, no structural validation","pmids":["37208557"],"is_preprint":false},{"year":2024,"finding":"PLCB1 facilitates proteasomal degradation of β-catenin and active-β-catenin by increasing the proportion of ubiquitinated β-catenin in a destruction complex-independent mechanism. When PLCB1 is downregulated (by miR-1290 induced by increased oxygen), active-β-catenin accumulates and Wnt signaling is boosted, promoting chemoresistance in glioma cells.","method":"miR-1290 overexpression/inhibition, PLCB1 knockdown/overexpression, ubiquitination assays, Western blot for β-catenin, in vivo glioma mouse model, WNT974 pharmacological inhibition","journal":"Drug resistance updates","confidence":"Medium","confidence_rationale":"Tier 2-3 / Moderate — ubiquitination assay supports mechanism, in vivo confirmation; single lab","pmids":["39053384"],"is_preprint":false},{"year":2024,"finding":"The FOS transcription factor directly promotes PLCB1 transcription, and the resulting PLCB1 activates PI3K/AKT signaling to induce radioresistance and weaken CD8+ T cell antitumor effects in triple-negative breast cancer. FOS knockdown phenocopies PLCB1 knockdown, and PI3K/AKT activator or PLCB1 overexpression rescues the phenotype after PLCB1/FOS depletion.","method":"PLCB1 and FOS siRNA knockdown, overexpression, PI3K/AKT activator rescue experiments, colony formation, apoptosis, tumorigenesis in mice, CD8+ T cell co-culture assays","journal":"Molecular carcinogenesis","confidence":"Medium","confidence_rationale":"Tier 2-3 / Moderate — epistasis established by rescue experiment, in vivo validation; single lab","pmids":["39451071"],"is_preprint":false},{"year":2021,"finding":"Plcb1 heterozygous knockout mice show reduced cue-induced reinstatement of cocaine-seeking behavior after extinction, with transcriptomic alterations in the medial prefrontal cortex related to dopaminergic synapse and long-term potentiation pathways. These mice also showed increased anxiety and impaired short-term memory.","method":"Plcb1+/- mouse model, operant self-administration and reinstatement paradigm, RNA sequencing of medial prefrontal cortex","journal":"Translational psychiatry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic loss-of-function with defined behavioral phenotype and transcriptomic pathway placement; single lab","pmids":["34635637"],"is_preprint":false},{"year":2022,"finding":"PLCB1 overexpression abrogated caerulein-induced inflammatory damage in pancreatic cells. SNHG11 acts as a sponge for miR-7-5p, thereby upregulating PLCB1, and this SNHG11/miR-7-5p/PLCB1 axis inhibits acute pancreatitis progression by participating in the p38MAPK signaling pathway.","method":"Dual-luciferase reporter assay and RIP assay (miR-7-5p–PLCB1 and miR-7-5p–SNHG11 interaction), PLCB1 overexpression/shRNA, in vivo AP model, p38MAPK pathway readouts","journal":"Cells","confidence":"Medium","confidence_rationale":"Tier 2-3 / Moderate — direct target validation by dual-luciferase and RIP, functional rescue, single lab","pmids":["36611865"],"is_preprint":false}],"current_model":"PLCB1 encodes a phosphoinositide-specific phospholipase C (PI-PLC) whose central region harbors the catalytic domain; it hydrolyzes PI(4,5)P2 at the plasma membrane and signals downstream through multiple pathways including PI3K/AKT/GSK3β/Snail (promoting EMT), RhoA/LIMK/Cofilin (actin remodeling), proteasomal degradation of β-catenin (suppressing Wnt signaling), and p38MAPK modulation; its transcription is directly activated by the EGR-1 transcription factor and by FOS, and in the brain it is required for normal neuronal signaling, with loss-of-function causing early-onset epileptic encephalopathy and haploinsufficiency reducing cocaine-cue-induced reinstatement."},"narrative":{"mechanistic_narrative":"PLCB1 encodes a ~150 kDa phosphoinositide-specific phospholipase C whose central region constitutes the catalytic domain and whose enzymatic activity was confirmed by reconstitution from cloned cDNA [PMID:2455601]; its hydrolysis of plasma membrane PI(4,5)P2 underpins its role as a signaling node coupling lipid metabolism to cytoskeletal and transcriptional programs [PMID:37208557]. Through PI3K/AKT signaling, PLCB1 drives epithelial-to-mesenchymal transition via the GSK3β/Snail axis and confers therapy resistance across multiple cancers, an output amplified by physical interaction with PABPC1 and PI3K [PMID:34580062, PMID:37208557]. In parallel, PLCB1 remodels the actin cytoskeleton through the RhoA/LIMK/Cofilin pathway to promote migration and invasion [PMID:37208557], and it suppresses Wnt signaling by promoting destruction-complex-independent ubiquitination and proteasomal degradation of β-catenin [PMID:39053384]. PLCB1 expression is directly controlled at the transcriptional level by EGR-1 [PMID:25192965] and FOS [PMID:39451071], and is further tuned post-transcriptionally by microRNA networks (miR-1290, miR-7-5p) that modulate its abundance in disease contexts [PMID:39053384, PMID:36611865]. In the brain, Plcb1 is required for normal neuronal function, with heterozygous loss altering prefrontal cortex transcriptomes and reducing cue-induced reinstatement of cocaine-seeking [PMID:34635637].","teleology":[{"year":1988,"claim":"Established that the PLCB1 cDNA encodes a catalytically active phosphoinositide-specific phospholipase C, defining its core biochemical identity and locating the catalytic domain to the central region.","evidence":"cDNA cloning with transient expression in COS-1 cells and homology-based domain assignment","pmids":["2455601"],"confidence":"High","gaps":["No structural model of the catalytic domain","Regulation of enzymatic activity not addressed","In vivo substrate dynamics not measured"]},{"year":2014,"claim":"Resolved how PLCB1 transcription is controlled by mapping its promoter and identifying EGR-1 as a direct upstream activator.","evidence":"5'-RACE, luciferase reporter deletion constructs, EMSA, and EGR-1 overexpression in multiple cell lines","pmids":["25192965"],"confidence":"High","gaps":["Physiological stimuli driving EGR-1-dependent PLCB1 induction not defined","Other promoter regulators not characterized"]},{"year":2021,"claim":"Connected PLCB1 to oncogenic PI3K/AKT signaling, showing it drives EMT and chemoresistance and physically partners with PABPC1 and PI3K.","evidence":"Co-IP, siRNA/overexpression, transposon in vivo tumorigenesis, and AKT inhibitor rescue in cholangiocarcinoma cells","pmids":["34580062"],"confidence":"Medium","gaps":["Co-IP interactions lack reciprocal/structural validation","Whether catalytic activity is required for AKT activation untested","Single tumor type and single lab"]},{"year":2021,"claim":"Identified HDAC8 as an upstream driver of PLCB1 expression linking epigenetic regulation to MEK inhibitor resistance via AKT.","evidence":"Microarray plus qPCR, siRNA of HDAC8 and PLCB1, HDAC8 inhibitors, and AKT activity assays","pmids":["34064422"],"confidence":"Medium","gaps":["Mechanism by which HDAC8 regulates the PLCB1 locus not resolved","Direct vs indirect transcriptional effect unclear","Single lab"]},{"year":2021,"claim":"Placed PLCB1 in neuronal signaling in vivo, showing heterozygous loss alters prefrontal cortex transcriptomes and addiction-related behavior.","evidence":"Plcb1+/- mouse operant reinstatement paradigm with prefrontal cortex RNA sequencing","pmids":["34635637"],"confidence":"Medium","gaps":["Molecular link from PLCB1 loss to dopaminergic/LTP pathway changes not mechanistic","Cell-type-specific contributions undefined","Single lab"]},{"year":2022,"claim":"Showed PLCB1 is anti-inflammatory in pancreatitis and is post-transcriptionally controlled by an SNHG11/miR-7-5p axis acting through p38MAPK.","evidence":"Dual-luciferase and RIP target validation, overexpression/shRNA, and in vivo acute pancreatitis model","pmids":["36611865"],"confidence":"Medium","gaps":["How PLCB1 modulates p38MAPK mechanistically unresolved","Whether enzymatic activity mediates the protective effect untested","Single lab"]},{"year":2023,"claim":"Defined a dual mechanism in which PLCB1 drives both actin remodeling via RhoA/LIMK/Cofilin and EMT via AKT, tied to its regulation of plasma membrane PI(4,5)P2.","evidence":"siRNA/overexpression with migration/invasion assays and pathway Western blots in gastric cancer cells","pmids":["37208557"],"confidence":"Medium","gaps":["Direct causal link between PI(4,5)P2 changes and RhoA activation not established","No structural or live-imaging validation","Single lab"]},{"year":2024,"claim":"Revealed a non-canonical PLCB1 function: promoting destruction-complex-independent ubiquitination and degradation of β-catenin to suppress Wnt signaling, with miR-1290 as an upstream regulator.","evidence":"Ubiquitination assays, miR-1290 and PLCB1 manipulation, and in vivo glioma model with Wnt inhibitor","pmids":["39053384"],"confidence":"Medium","gaps":["Identity of the ubiquitin ligase machinery engaged not determined","Whether PLCB1 lipase activity is required unclear","Single lab"]},{"year":2024,"claim":"Established FOS as a second direct transcriptional activator of PLCB1, linking PLCB1-driven AKT signaling to radioresistance and suppressed CD8+ T cell antitumor immunity.","evidence":"FOS/PLCB1 knockdown and overexpression, epistasis via PI3K/AKT activator rescue, and CD8+ T cell co-culture in TNBC","pmids":["39451071"],"confidence":"Medium","gaps":["Direct FOS binding site on PLCB1 promoter not mapped in detail","Mechanism linking tumor PLCB1 to T cell function indirect","Single lab"]},{"year":null,"claim":"It remains unresolved whether PLCB1 catalytic PI(4,5)P2 hydrolysis is mechanistically required for its diverse downstream outputs (AKT, RhoA, β-catenin, p38MAPK), and how a single lipase coordinates these distinct programs in a tissue-specific manner.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No experiments separating catalytic from scaffolding functions","No structural basis for partner selectivity","Tissue-specific signaling logic uncharacterized"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140098","term_label":"catalytic activity, acting on RNA","supporting_discovery_ids":[0]},{"term_id":"GO:0016787","term_label":"hydrolase activity","supporting_discovery_ids":[0]},{"term_id":"GO:0008289","term_label":"lipid binding","supporting_discovery_ids":[0,4]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[4]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[2,4,6]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[2,3,5,6]}],"complexes":[],"partners":["PABPC1","PI3K"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q9NQ66","full_name":"1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase beta-1","aliases":["PLC-154","Phosphoinositide phospholipase C-beta-1","Phospholipase C-I","PLC-I","Phospholipase C-beta-1","PLC-beta-1"],"length_aa":1216,"mass_kda":138.6,"function":"Catalyzes the hydrolysis of 1-phosphatidylinositol 4,5-bisphosphate into diacylglycerol (DAG) and inositol 1,4,5-trisphosphate (IP3) and mediates intracellular signaling downstream of G protein-coupled receptors (PubMed:9188725). Regulates the function of the endothelial barrier","subcellular_location":"Nucleus membrane; Cytoplasm","url":"https://www.uniprot.org/uniprotkb/Q9NQ66/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/PLCB1","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/PLCB1","total_profiled":1310},"omim":[{"mim_id":"613722","title":"DEVELOPMENTAL AND EPILEPTIC ENCEPHALOPATHY 12; DEE12","url":"https://www.omim.org/entry/613722"},{"mim_id":"611768","title":"MICRO RNA 335; MIR335","url":"https://www.omim.org/entry/611768"},{"mim_id":"610392","title":"MYC-BINDING PROTEIN 2; MYCBP2","url":"https://www.omim.org/entry/610392"},{"mim_id":"607120","title":"PHOSPHOLIPASE C, BETA-1; PLCB1","url":"https://www.omim.org/entry/607120"},{"mim_id":"605692","title":"TRANSIENT RECEPTOR POTENTIAL CATION CHANNEL, SUBFAMILY M, MEMBER 7; TRPM7","url":"https://www.omim.org/entry/605692"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Plasma membrane","reliability":"Approved"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in all","driving_tissues":[{"tissue":"brain","ntpm":44.7}],"url":"https://www.proteinatlas.org/search/PLCB1"},"hgnc":{"alias_symbol":["KIAA0581","PLC-I","PLC154"],"prev_symbol":[]},"alphafold":{"accession":"Q9NQ66","domains":[{"cath_id":"2.30.29.240","chopping":"19-218","consensus_level":"medium","plddt":92.5776,"start":19,"end":218},{"cath_id":"1.10.238.10","chopping":"222-304","consensus_level":"high","plddt":93.8065,"start":222,"end":304},{"cath_id":"3.20.20.190","chopping":"321-470_528-654","consensus_level":"medium","plddt":95.5413,"start":321,"end":654},{"cath_id":"2.60.40.150","chopping":"675-804","consensus_level":"high","plddt":95.596,"start":675,"end":804},{"cath_id":"1.20.1230.10","chopping":"908-968_997-1050_1120-1168","consensus_level":"medium","plddt":91.682,"start":908,"end":1168}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9NQ66","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q9NQ66-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q9NQ66-F1-predicted_aligned_error_v6.png","plddt_mean":83.62},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=PLCB1","jax_strain_url":"https://www.jax.org/strain/search?query=PLCB1"},"sequence":{"accession":"Q9NQ66","fasta_url":"https://rest.uniprot.org/uniprotkb/Q9NQ66.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q9NQ66/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9NQ66"}},"corpus_meta":[{"pmid":"2455601","id":"PMC_2455601","title":"Determination of the primary structure of PLC-154 demonstrates diversity of phosphoinositide-specific phospholipase C activities.","date":"1988","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/2455601","citation_count":145,"is_preprint":false},{"pmid":"34580062","id":"PMC_34580062","title":"A PLCB1-PI3K-AKT Signaling Axis Activates EMT to Promote Cholangiocarcinoma Progression.","date":"2021","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/34580062","citation_count":88,"is_preprint":false},{"pmid":"22690784","id":"PMC_22690784","title":"Homozygous PLCB1 deletion associated with malignant migrating partial seizures in infancy.","date":"2012","source":"Epilepsia","url":"https://pubmed.ncbi.nlm.nih.gov/22690784","citation_count":70,"is_preprint":false},{"pmid":"22507702","id":"PMC_22507702","title":"Deletion of PLCB1 gene in schizophrenia-affected patients.","date":"2012","source":"Journal of cellular and molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/22507702","citation_count":58,"is_preprint":false},{"pmid":"26434682","id":"PMC_26434682","title":"Genetic variants in PLCB4/PLCB1 as susceptibility loci for coronary artery aneurysm formation in Kawasaki disease in Han Chinese in Taiwan.","date":"2015","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/26434682","citation_count":33,"is_preprint":false},{"pmid":"30657554","id":"PMC_30657554","title":"MicroRNA-124 inhibits colorectal cancer cell proliferation and suppresses tumor growth by interacting with PLCB1 and regulating Wnt/β-catenin signaling pathway.","date":"2019","source":"European review for medical and pharmacological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/30657554","citation_count":30,"is_preprint":false},{"pmid":"38387756","id":"PMC_38387756","title":"Lnc-PLCB1 is stabilized by METTL14 induced m6A modification and inhibits Helicobacter pylori mediated gastric cancer by destabilizing DDX21.","date":"2024","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/38387756","citation_count":27,"is_preprint":false},{"pmid":"29895226","id":"PMC_29895226","title":"Down-regulation of circ-PRKCI inhibits cell migration and proliferation in Hirschsprung disease by suppressing the expression of miR-1324 target PLCB1.","date":"2018","source":"Cell cycle (Georgetown, Tex.)","url":"https://pubmed.ncbi.nlm.nih.gov/29895226","citation_count":23,"is_preprint":false},{"pmid":"24684524","id":"PMC_24684524","title":"Severe infantile epileptic encephalopathy due to mutations in PLCB1: expansion of the genotypic and phenotypic disease spectrum.","date":"2014","source":"Developmental medicine and child neurology","url":"https://pubmed.ncbi.nlm.nih.gov/24684524","citation_count":20,"is_preprint":false},{"pmid":"37208557","id":"PMC_37208557","title":"PLCB1 Enhances Cell Migration and Invasion in Gastric Cancer Via Regulating Actin Cytoskeletal Remodeling and Epithelial-Mesenchymal Transition.","date":"2023","source":"Biochemical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/37208557","citation_count":15,"is_preprint":false},{"pmid":"36611865","id":"PMC_36611865","title":"Effect of SNHG11/miR-7-5p/PLCB1 Axis on Acute Pancreatitis through Inhibiting p38MAPK Pathway.","date":"2022","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/36611865","citation_count":15,"is_preprint":false},{"pmid":"34064422","id":"PMC_34064422","title":"HDAC8 Activates AKT through Upregulating PLCB1 and Suppressing DESC1 Expression in MEK1/2 Inhibition-Resistant Cells.","date":"2021","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/34064422","citation_count":14,"is_preprint":false},{"pmid":"31883110","id":"PMC_31883110","title":"Three novel patients with epileptic encephalopathy due to biallelic mutations in the PLCB1 gene.","date":"2020","source":"Clinical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/31883110","citation_count":13,"is_preprint":false},{"pmid":"28860459","id":"PMC_28860459","title":"Association of the PLCB1 gene with drug dependence.","date":"2017","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/28860459","citation_count":12,"is_preprint":false},{"pmid":"39053384","id":"PMC_39053384","title":"Increased oxygen stimulation promotes chemoresistance and phenotype shifting through PLCB1 in gliomas.","date":"2024","source":"Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy","url":"https://pubmed.ncbi.nlm.nih.gov/39053384","citation_count":11,"is_preprint":false},{"pmid":"33559088","id":"PMC_33559088","title":"Circ_0091579 Serves as a Tumor-Promoting Factor in Hepatocellular Carcinoma Through miR-1225-5p/PLCB1 Axis.","date":"2021","source":"Digestive diseases and sciences","url":"https://pubmed.ncbi.nlm.nih.gov/33559088","citation_count":11,"is_preprint":false},{"pmid":"37063368","id":"PMC_37063368","title":"Dodecyl creatine ester improves cognitive function and identifies key protein drivers including KIF1A and PLCB1 in a mouse model of creatine transporter deficiency.","date":"2023","source":"Frontiers in molecular neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/37063368","citation_count":8,"is_preprint":false},{"pmid":"25192965","id":"PMC_25192965","title":"Characterization of the PLCB1 promoter and regulation by early growth response transcription factor EGR-1.","date":"2014","source":"European journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/25192965","citation_count":7,"is_preprint":false},{"pmid":"39451071","id":"PMC_39451071","title":"FOS-Mediated PLCB1 Induces Radioresistance and Weakens the Antitumor Effects of CD8+ T Cells in Triple-Negative Breast Cancer.","date":"2024","source":"Molecular carcinogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/39451071","citation_count":6,"is_preprint":false},{"pmid":"38778543","id":"PMC_38778543","title":"LncRNA AC100826.1 regulated PLCB1 to promote progression in non-small cell lung cancer.","date":"2024","source":"Thoracic cancer","url":"https://pubmed.ncbi.nlm.nih.gov/38778543","citation_count":4,"is_preprint":false},{"pmid":"34635637","id":"PMC_34635637","title":"Reduced cue-induced reinstatement of cocaine-seeking behavior in Plcb1 +/- mice.","date":"2021","source":"Translational psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/34635637","citation_count":4,"is_preprint":false},{"pmid":"37441061","id":"PMC_37441061","title":"Refractory Jeavons Syndrome from Birth Symptomatic to PLCB1 Mutation.","date":"2023","source":"Child neurology open","url":"https://pubmed.ncbi.nlm.nih.gov/37441061","citation_count":3,"is_preprint":false},{"pmid":"38931955","id":"PMC_38931955","title":"Single-Cell Transcriptomic and Targeted Genomic Profiling Adjusted for Inflammation and Therapy Bias Reveal CRTAM and PLCB1 as Novel Hub Genes for Anti-Tumor Necrosis Factor Alpha Therapy Response in Crohn's Disease.","date":"2024","source":"Pharmaceutics","url":"https://pubmed.ncbi.nlm.nih.gov/38931955","citation_count":2,"is_preprint":false},{"pmid":"34129193","id":"PMC_34129193","title":"Investigation of high correlation with carcass traits of SNPs of the PLCB1, C/EBPα, and TDRKH genes and the combinations of SNPs using the MDR method in the Hanwoo.","date":"2021","source":"Genes & genomics","url":"https://pubmed.ncbi.nlm.nih.gov/34129193","citation_count":1,"is_preprint":false},{"pmid":"38731807","id":"PMC_38731807","title":"Elucidating the Role of circTIAM1 in Guangling Large-Tailed Sheep Adipocyte Proliferation and Differentiation via the miR-485-3p/PLCB1 Pathway.","date":"2024","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/38731807","citation_count":1,"is_preprint":false},{"pmid":"39219848","id":"PMC_39219848","title":"Corrigendum to \"Refractory Jeavons Syndrome from Birth Symptomatic to PLCB1 Mutation\".","date":"2024","source":"Child neurology open","url":"https://pubmed.ncbi.nlm.nih.gov/39219848","citation_count":0,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":14881,"output_tokens":2533,"usd":0.041319,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":9621,"output_tokens":3236,"usd":0.064503,"stage2_stop_reason":"end_turn"},"total_usd":0.105822,"stage1_batch_id":"msgbatch_01CNoDbkChHEkgrJnL7BwtGJ","stage2_batch_id":"msgbatch_016Y4x9E9Wg5VQDANj9quSQD","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1988,\n      \"finding\": \"PLC-154 (PLCB1) encodes a functional phosphoinositide-specific phospholipase C of ~150 kDa. The central region of PLC-154 shares homology with PLC-148 and was assigned as the putative catalytic domain. Transient expression in COS-1 cells confirmed the encoded protein is enzymatically active.\",\n      \"method\": \"cDNA cloning, transient expression in COS-1 cells, protein sequence analysis, Southern/Northern blotting\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — direct reconstitution of enzymatic activity from cloned cDNA, domain assignment by sequence homology with functional validation\",\n      \"pmids\": [\"2455601\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"The PLCB1 promoter was characterized for the first time; transcription initiates from multiple start points, with the main start at nt-235 relative to the translation start. A specific EGR-1 binding site was identified at nt-451/-419, and EGR-1 overexpression increased PLCB1 promoter activity more than 5-fold, placing EGR-1 as a direct transcriptional activator of PLCB1.\",\n      \"method\": \"5'-RACE, promoter cloning, luciferase reporter assays with deletion constructs, EMSA, EGR-1 overexpression in multiple cell lines\",\n      \"journal\": \"European journal of pharmacology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — multiple orthogonal methods (EMSA, luciferase deletion constructs, overexpression) in a single focused study\",\n      \"pmids\": [\"25192965\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"PLCB1 activates PI3K/AKT signaling to induce epithelial-to-mesenchymal transition (EMT) in cholangiocarcinoma cells. PABPC1 physically interacts with PLCB1 and PI3K to amplify PLCB1-mediated EMT via the PI3K/AKT/GSK3β/Snail axis. PLCB1-driven AKT activation also confers resistance to gemcitabine/cisplatin, reversible by the AKT inhibitor MK2206.\",\n      \"method\": \"Co-immunoprecipitation (PABPC1–PLCB1–PI3K interaction), transposon-based in vivo tumorigenesis models, siRNA knockdown/overexpression, drug treatment with pathway inhibitor\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 / Moderate — Co-IP for interaction, multiple functional assays, in vivo models; single lab\",\n      \"pmids\": [\"34580062\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"HDAC8 upregulates PLCB1 expression in MEK1/2 inhibitor-resistant cancer cells, and elevated PLCB1 activates AKT, contributing to resistance. HDAC8 inhibition suppresses PLCB1 expression and re-sensitizes resistant cells to MEK1/2 inhibition; PLCB1 siRNA similarly inhibits AKT activation.\",\n      \"method\": \"Affymetrix microarray followed by qPCR validation, siRNA knockdown of HDAC8 and PLCB1, HDAC8 inhibitors, expression vectors, AKT activity assays\",\n      \"journal\": \"Cells\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 / Moderate — multiple orthogonal methods (microarray + qPCR + siRNA + inhibitor), single lab\",\n      \"pmids\": [\"34064422\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"PLCB1 promotes gastric cancer cell migration and invasion by mediating actin cytoskeletal remodeling via the RhoA/LIMK/Cofilin pathway and by promoting EMT through AKT signaling. PLCB1 regulates the abundance of PI(4,5)P2 at the plasma membrane as part of this mechanism.\",\n      \"method\": \"siRNA knockdown, overexpression, cell migration/invasion assays, Western blot for RhoA/LIMK/Cofilin and AKT pathway components\",\n      \"journal\": \"Biochemical genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 / Moderate — loss- and gain-of-function with specific pathway readouts; single lab, no structural validation\",\n      \"pmids\": [\"37208557\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"PLCB1 facilitates proteasomal degradation of β-catenin and active-β-catenin by increasing the proportion of ubiquitinated β-catenin in a destruction complex-independent mechanism. When PLCB1 is downregulated (by miR-1290 induced by increased oxygen), active-β-catenin accumulates and Wnt signaling is boosted, promoting chemoresistance in glioma cells.\",\n      \"method\": \"miR-1290 overexpression/inhibition, PLCB1 knockdown/overexpression, ubiquitination assays, Western blot for β-catenin, in vivo glioma mouse model, WNT974 pharmacological inhibition\",\n      \"journal\": \"Drug resistance updates\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 / Moderate — ubiquitination assay supports mechanism, in vivo confirmation; single lab\",\n      \"pmids\": [\"39053384\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"The FOS transcription factor directly promotes PLCB1 transcription, and the resulting PLCB1 activates PI3K/AKT signaling to induce radioresistance and weaken CD8+ T cell antitumor effects in triple-negative breast cancer. FOS knockdown phenocopies PLCB1 knockdown, and PI3K/AKT activator or PLCB1 overexpression rescues the phenotype after PLCB1/FOS depletion.\",\n      \"method\": \"PLCB1 and FOS siRNA knockdown, overexpression, PI3K/AKT activator rescue experiments, colony formation, apoptosis, tumorigenesis in mice, CD8+ T cell co-culture assays\",\n      \"journal\": \"Molecular carcinogenesis\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 / Moderate — epistasis established by rescue experiment, in vivo validation; single lab\",\n      \"pmids\": [\"39451071\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Plcb1 heterozygous knockout mice show reduced cue-induced reinstatement of cocaine-seeking behavior after extinction, with transcriptomic alterations in the medial prefrontal cortex related to dopaminergic synapse and long-term potentiation pathways. These mice also showed increased anxiety and impaired short-term memory.\",\n      \"method\": \"Plcb1+/- mouse model, operant self-administration and reinstatement paradigm, RNA sequencing of medial prefrontal cortex\",\n      \"journal\": \"Translational psychiatry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic loss-of-function with defined behavioral phenotype and transcriptomic pathway placement; single lab\",\n      \"pmids\": [\"34635637\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"PLCB1 overexpression abrogated caerulein-induced inflammatory damage in pancreatic cells. SNHG11 acts as a sponge for miR-7-5p, thereby upregulating PLCB1, and this SNHG11/miR-7-5p/PLCB1 axis inhibits acute pancreatitis progression by participating in the p38MAPK signaling pathway.\",\n      \"method\": \"Dual-luciferase reporter assay and RIP assay (miR-7-5p–PLCB1 and miR-7-5p–SNHG11 interaction), PLCB1 overexpression/shRNA, in vivo AP model, p38MAPK pathway readouts\",\n      \"journal\": \"Cells\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 / Moderate — direct target validation by dual-luciferase and RIP, functional rescue, single lab\",\n      \"pmids\": [\"36611865\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"PLCB1 encodes a phosphoinositide-specific phospholipase C (PI-PLC) whose central region harbors the catalytic domain; it hydrolyzes PI(4,5)P2 at the plasma membrane and signals downstream through multiple pathways including PI3K/AKT/GSK3β/Snail (promoting EMT), RhoA/LIMK/Cofilin (actin remodeling), proteasomal degradation of β-catenin (suppressing Wnt signaling), and p38MAPK modulation; its transcription is directly activated by the EGR-1 transcription factor and by FOS, and in the brain it is required for normal neuronal signaling, with loss-of-function causing early-onset epileptic encephalopathy and haploinsufficiency reducing cocaine-cue-induced reinstatement.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"PLCB1 encodes a ~150 kDa phosphoinositide-specific phospholipase C whose central region constitutes the catalytic domain and whose enzymatic activity was confirmed by reconstitution from cloned cDNA [#0]; its hydrolysis of plasma membrane PI(4,5)P2 underpins its role as a signaling node coupling lipid metabolism to cytoskeletal and transcriptional programs [#4]. Through PI3K/AKT signaling, PLCB1 drives epithelial-to-mesenchymal transition via the GSK3\\u03b2/Snail axis and confers therapy resistance across multiple cancers, an output amplified by physical interaction with PABPC1 and PI3K [#2, #4]. In parallel, PLCB1 remodels the actin cytoskeleton through the RhoA/LIMK/Cofilin pathway to promote migration and invasion [#4], and it suppresses Wnt signaling by promoting destruction-complex-independent ubiquitination and proteasomal degradation of \\u03b2-catenin [#5]. PLCB1 expression is directly controlled at the transcriptional level by EGR-1 [#1] and FOS [#6], and is further tuned post-transcriptionally by microRNA networks (miR-1290, miR-7-5p) that modulate its abundance in disease contexts [#5, #8]. In the brain, Plcb1 is required for normal neuronal function, with heterozygous loss altering prefrontal cortex transcriptomes and reducing cue-induced reinstatement of cocaine-seeking [#7].\",\n  \"teleology\": [\n    {\n      \"year\": 1988,\n      \"claim\": \"Established that the PLCB1 cDNA encodes a catalytically active phosphoinositide-specific phospholipase C, defining its core biochemical identity and locating the catalytic domain to the central region.\",\n      \"evidence\": \"cDNA cloning with transient expression in COS-1 cells and homology-based domain assignment\",\n      \"pmids\": [\"2455601\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"No structural model of the catalytic domain\",\n        \"Regulation of enzymatic activity not addressed\",\n        \"In vivo substrate dynamics not measured\"\n      ]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Resolved how PLCB1 transcription is controlled by mapping its promoter and identifying EGR-1 as a direct upstream activator.\",\n      \"evidence\": \"5'-RACE, luciferase reporter deletion constructs, EMSA, and EGR-1 overexpression in multiple cell lines\",\n      \"pmids\": [\"25192965\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Physiological stimuli driving EGR-1-dependent PLCB1 induction not defined\",\n        \"Other promoter regulators not characterized\"\n      ]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Connected PLCB1 to oncogenic PI3K/AKT signaling, showing it drives EMT and chemoresistance and physically partners with PABPC1 and PI3K.\",\n      \"evidence\": \"Co-IP, siRNA/overexpression, transposon in vivo tumorigenesis, and AKT inhibitor rescue in cholangiocarcinoma cells\",\n      \"pmids\": [\"34580062\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Co-IP interactions lack reciprocal/structural validation\",\n        \"Whether catalytic activity is required for AKT activation untested\",\n        \"Single tumor type and single lab\"\n      ]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Identified HDAC8 as an upstream driver of PLCB1 expression linking epigenetic regulation to MEK inhibitor resistance via AKT.\",\n      \"evidence\": \"Microarray plus qPCR, siRNA of HDAC8 and PLCB1, HDAC8 inhibitors, and AKT activity assays\",\n      \"pmids\": [\"34064422\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Mechanism by which HDAC8 regulates the PLCB1 locus not resolved\",\n        \"Direct vs indirect transcriptional effect unclear\",\n        \"Single lab\"\n      ]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Placed PLCB1 in neuronal signaling in vivo, showing heterozygous loss alters prefrontal cortex transcriptomes and addiction-related behavior.\",\n      \"evidence\": \"Plcb1+/- mouse operant reinstatement paradigm with prefrontal cortex RNA sequencing\",\n      \"pmids\": [\"34635637\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Molecular link from PLCB1 loss to dopaminergic/LTP pathway changes not mechanistic\",\n        \"Cell-type-specific contributions undefined\",\n        \"Single lab\"\n      ]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Showed PLCB1 is anti-inflammatory in pancreatitis and is post-transcriptionally controlled by an SNHG11/miR-7-5p axis acting through p38MAPK.\",\n      \"evidence\": \"Dual-luciferase and RIP target validation, overexpression/shRNA, and in vivo acute pancreatitis model\",\n      \"pmids\": [\"36611865\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"How PLCB1 modulates p38MAPK mechanistically unresolved\",\n        \"Whether enzymatic activity mediates the protective effect untested\",\n        \"Single lab\"\n      ]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Defined a dual mechanism in which PLCB1 drives both actin remodeling via RhoA/LIMK/Cofilin and EMT via AKT, tied to its regulation of plasma membrane PI(4,5)P2.\",\n      \"evidence\": \"siRNA/overexpression with migration/invasion assays and pathway Western blots in gastric cancer cells\",\n      \"pmids\": [\"37208557\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Direct causal link between PI(4,5)P2 changes and RhoA activation not established\",\n        \"No structural or live-imaging validation\",\n        \"Single lab\"\n      ]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Revealed a non-canonical PLCB1 function: promoting destruction-complex-independent ubiquitination and degradation of \\u03b2-catenin to suppress Wnt signaling, with miR-1290 as an upstream regulator.\",\n      \"evidence\": \"Ubiquitination assays, miR-1290 and PLCB1 manipulation, and in vivo glioma model with Wnt inhibitor\",\n      \"pmids\": [\"39053384\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Identity of the ubiquitin ligase machinery engaged not determined\",\n        \"Whether PLCB1 lipase activity is required unclear\",\n        \"Single lab\"\n      ]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Established FOS as a second direct transcriptional activator of PLCB1, linking PLCB1-driven AKT signaling to radioresistance and suppressed CD8+ T cell antitumor immunity.\",\n      \"evidence\": \"FOS/PLCB1 knockdown and overexpression, epistasis via PI3K/AKT activator rescue, and CD8+ T cell co-culture in TNBC\",\n      \"pmids\": [\"39451071\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Direct FOS binding site on PLCB1 promoter not mapped in detail\",\n        \"Mechanism linking tumor PLCB1 to T cell function indirect\",\n        \"Single lab\"\n      ]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"It remains unresolved whether PLCB1 catalytic PI(4,5)P2 hydrolysis is mechanistically required for its diverse downstream outputs (AKT, RhoA, \\u03b2-catenin, p38MAPK), and how a single lipase coordinates these distinct programs in a tissue-specific manner.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"No experiments separating catalytic from scaffolding functions\",\n        \"No structural basis for partner selectivity\",\n        \"Tissue-specific signaling logic uncharacterized\"\n      ]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140098\", \"supporting_discovery_ids\": [0]},\n      {\"term_id\": \"GO:0016787\", \"supporting_discovery_ids\": [0]},\n      {\"term_id\": \"GO:0008289\", \"supporting_discovery_ids\": [0, 4]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [4]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [2, 4, 6]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [2, 3, 5, 6]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"PABPC1\",\n      \"PI3K\"\n    ],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"tie","faith_supported":5,"faith_total":5,"faith_pct":100.0}}